Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

Figures & data

Figure 1. Scheme summarizing the characteristics of patients potentially eligible to tildrakizumab 200 mg. DTT: difficult-to-treat; prior therapy failure: prior therapy with at least one biologic failed or resulted in a partial response; comorbidities: cardio‐metabolic comorbidities (including cardiovascular diseases, arterial hypertension, type 2 diabetes mellitus, hyperlipidemia and metabolic syndrome) or psoriatic arthritis.